Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 2/20 | 0.61 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.48 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.48 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.48 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.48 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12497423 | 1.00 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL27952288 | 1.00 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4CYP2D6CYP2C19 | |
| SCHEMBL167264 | 0.98 | CHRNB2 (0.63) | CHRNB2CHRNA7CHRNA4CYP2D6CYP2C19 | |
| SCHEMBL21232 | 0.98 | CHRNB2 (0.63) | CHRNB2CHRNA7CHRNA4CYP2D6CYP2C19 | |
| SCHEMBL170704 | 0.98 | CHRNB2 (0.63) | CHRNB2CHRNA7CHRNA4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL28855198 | 0.96 | CYP2D6 (0.61) | CHRNB2CHRNA7CHRNA4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL28855199 | 0.96 | CYP2D6 (0.61) | CHRNB2CHRNA7CHRNA4CYP2D6CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL3517185 | 0.96 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL20449216 | 0.94 | MEN1 (0.62) | CHRNB2CHRNA7CHRNA4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL2522634 | 0.94 | CHRNB2 (0.65) | CHRNB2CHRNA7CHRNA4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-11-14 | — | — | US | disclosed |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | BIOARDIS LLC | 2023-02-02 | — | — | US | disclosed |
| US-20220332723-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-10-20 | — | — | US | disclosed |
| CN-114945578-A | Compounds as CD73 inhibitors | 博奥阿迪斯生物科技公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-3638229-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | Biocryst Pharmaceuticals, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018232094-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| CN-103635472-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2018-01-12 | — | — | CN | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1957058-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1773821-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060252778-A1 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | MERCK SHARP & DOHME CORP. | 2006-11-09 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | TRPV1, TRPM2, TRPM6 | CHRNA7 169/4885CHRM5 84/4885CHRM3 53/4885 |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | CHRNA7 4356/4885CHRM5 4536/4885CHRM3 4610/4885 |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | ENTPD5, ENTPD1, NT5E | CHRNA7 1015/4885CHRM5 1652/4885CHRM3 1914/4885 |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | CHRNA7 4022/4885CHRM5 4637/4885CHRM3 3677/4885 |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | CHRNA7 4022/4885CHRM5 4637/4885CHRM3 3677/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | CHRNA7 3706/4885CHRM5 4426/4885CHRM3 4216/4885 |
| US-20060252778-A1 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | ADAM17, ADAMTS1, ADAM10 | CHRNA7 3805/4885CHRM5 4618/4885CHRM3 4029/4885 |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | CHRNA7 4022/4885CHRM5 4637/4885CHRM3 3677/4885 |
| US-20220332723-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | CHRNA7 4022/4885CHRM5 4637/4885CHRM3 3677/4885 |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | CHRNA7 4022/4885CHRM5 4637/4885CHRM3 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.